Dutasteride (Avodart) for Hair Loss & BPH — Skin & Hair
Dual 5-alpha reductase inhibitor (Type I & II) that reduces DHT by over 90%, FDA-approved for BPH with off-label use for hair loss.
Overview
Dutasteride is a dual 5-alpha reductase inhibitor that blocks both type I and type II isoenzymes, achieving over 90% suppression of serum DHT — significantly more than finasteride's ~70% suppression. Type I 5-alpha reductase is found predominantly in sebaceous glands, liver, and skin, while type II predominates in prostate and hair follicles. By inhibiting both isoforms, dutasteride provides more complete androgen blockade. FDA-approved for BPH at 0.5 mg daily, dutasteride has extensive off-label use for androgenetic alopecia where it has demonstrated superiority to finasteride in head-to-head trials. A landmark Korean RCT (Olsen et al., 2006; Jung et al., 2014) showed dutasteride 0.5 mg produced significantly greater hair count increases compared to finasteride 1 mg at 24 weeks. Dutasteride has a very long half-life of 5 weeks at steady state, meaning effects persist for months after discontinuation. This extended duration has implications for both efficacy and the management of side effects.
Indications
- FDA-approved: Benign prostatic hyperplasia (BPH) — Avodart 0.5 mg
- FDA-approved (Japan, South Korea): Androgenetic alopecia — 0.5 mg
- Off-label (US/EU): Male pattern hair loss
- Off-label: DHT management during TRT when finasteride is insufficient
Mechanism of Action
Dutasteride inhibits both type I (skin, liver, sebaceous glands) and type II (prostate, hair follicles) 5-alpha reductase enzymes
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Dutasteride | 0.5 mg | Once daily | Standard dose for both BPH and off-label hair loss |
| Dutasteride | 0.5 mg | Once weekly | Off-label reduced frequency — some clinicians use for maintenance with fewer side effects |
| Dutasteride | 2.5 mg | Once weekly | Weekly dosing protocol — equivalent weekly exposure, anecdotal use |
Evidence Grade
GRADE A
Safety & Contraindications
- Similar sexual side effect profile to finasteride but potentially higher incidence: decreased libido (3%), erectile dysfunction (4.7%), ejaculatory disorders (1.4%)
- Very long half-life (5 weeks) — side effects persist long after discontinuation
- Contraindicated in women of childbearing potential — severe teratogen (Category X)
- Blood donation restricted for 6 months after last dose due to teratogenicity risk
- Reduces PSA by approximately 50% — double values for prostate cancer screening
- Gynecomastia and breast tenderness reported (1-2%)
- Potential for persistent sexual dysfunction after discontinuation (post-finasteride-like syndrome)